A Phase 1 Study of JNJ-88549968, a T-cell Redirecting Antibody, for CALR-mutated Myeloproliferative Neoplasms
88549968MPN1001
Phase 1 other active
Quick answer
A Phase 1 Study of JNJ-88549968, a T-cell Redirecting Antibody, for CALR-mutated Myeloproliferative Neoplasms for CALR-mutated Myeloproliferative Neoplasms is a Phase 1 program (other) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- CALR-mutated Myeloproliferative Neoplasms
- Phase
- Phase 1
- Modality
- other
- Status
- active